AIT Bioscience issued the following announcement on May 18.
Global Diagnostics Partnering Terms and Agreements 2014-2020
The "Global Diagnostics Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the world's leading companies.
Trends in Diagnostics dealmaking in the biopharma industry since 2014
Analysis of Diagnostics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Diagnostics deals
Access to Diagnostics contract documents
Leading Diagnostics deals by value since 2014
Most active Diagnostics dealmakers since 2014
The report provides a detailed understanding and analysis of how and why companies enter Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Diagnostics agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Diagnostics partnering deals.
The report presents financial deal term values for Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Diagnostics partnering field; both the leading deal values and most active Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 2,400 online deal records of actual Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Diagnostics dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Diagnostics deals announced by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Diagnostics partnering deals signed and announced since Jan 2014. The Chapter is organized by specific Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostics partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostics technologies and products.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Companies Mentioned
2bPrecise
3D Signatures
3M
3PrimeDx
4D Molecular Therapeutics
5-Diagnostics
7D Surgical
10X Genomics
14M Genomics
20/20 GeneSystems
23andMe
36 Strategies General Trading
1717 Life Science Ventures
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
AAM Healthcare
AB Analitica
Abaxis
Abbott Laboratories
Abbvie
Abcam
Abcodia
Abionic
Abramson Cancer Center
Acacia Research
Accelerate Diagnostics
Access BIO
AccuGenomics
Accuray
AccuRef Diagnostics
Accu Reference Medical Laboratory
Accuscience
AceCGT Life Science
Achaogen
AC Immune
Acon Labs
Acoustic MedSystems
Actelion
ACT Genomics
Acumen Pharmaceuticals
Acutus Medical
AdAlta
Adaptiiv
Adaptive Biotechnologies
ADC Therapeutics
ADMA Biologics
Admera Health
ADS
ADT Altona Diagnostic Technologies
Advanced Accelerator Applications
Advanced Animal Diagnostics
Advanced Biological Laboratories
Advanced Cell Diagnostics
Advanced Chemistry Development
Advanced Cooling Therapy
Advanced Genomic Solutions
Advanced Guidance Technologies
Advanced Medical German Company of Kuwait
Advanced Nuclear Medicine Ingredients
ADx Healthcare
Aelan Cell Technologies
Aerocrine
Aethlon Medical
Aetna
Affinium Pharmaceuticals
AFFiRiS
Affymetrix
Agena Bioscience
Agendia
Agfa HealthCare
Agilent Technologies
Agiomix FZ
Agios Pharmaceuticals
AG Mednet
Agricultural Research Service
AIM Specialty Health
Aircraft Medical
Air Force General Hospital
Air Force Research Laboratory
AirStrip Technologies
AIT Laboratories
Akers Biosciences
Akili Interactive Labs
Akonni Biosystems
AKSA Medical
Albany Molecular Research
Albert Einstein Healthcare Network
Aldeyra Therapeutics
Alere
Alexion Pharmaceuticals
Alibaba Health
Align Technology
AliveCor
ALK-Abello
Allakos
Allegheny Technologies
Allele Biotechnology and Pharmaceuticals
Allergan
AllerGenis
Alliance Global FZ
Alliance Global Group
Alliance Pharma
Allied Healthcare Products
Almac Diagnostics
Almac Group
Alnylam Pharmaceuticals
Alphaeon
Alpha Imaging
Alpinion Medical Systems
ALR Technologies
Alteris
Altris
Alverno Clinical Laboratories
Al Zahrawi Medical Supplies
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Alzheimers Research UK
Amarantus BioSciences
Amazon Web Services
Ambry Genetics
AMD Insight
A Menarini Diagnostics
America's Choice Provider Network
American Animal Hospital Association
American Diabetes Association
American Health Imaging
American Lung Association
American Medical Systems
American Pathology Partners
Amerinet
Amgen
Amos Gazit
Amoy Diagnostics
AmoyDx Diagnostics
Amplitech
AmpTec
AMRA
Amydis Diagnostics
Analogic
Analytics 4 Life
Analytics Engines
Anapure BioScientific
Anavex Life Sciences
Angle
Angsana Molecular & Diagnostics
Anika Therapeutics
Anixa Biosciences
Annoroad
Anpac Bio-Medical Science
Antaros Medical
Antech
Anteo Diagnostics
Anthem Bluecross
Apax Partners
Aperiomics
Apogenix
Appistry
Apple
and many, many more!
For more information about this report visit https://www.researchandmarkets.com/r/ukkgz4
View source version on businesswire.com:https://www.businesswire.com/news/home/20200518005497/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: BIOTECHNOLOGY SCIENCE HEALTH OTHER SCIENCE
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 05/18/2020 10:04 AM/DISC: 05/18/2020 10:04 AM
http://www.businesswire.com/news/home/20200518005497/en
Original source can be found here.